{"id":"W4412724750","doi":"10.1080/14796694.2025.2535280","title":"SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma","year":2025,"lang":"en","type":"article","venue":"Future Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Calgary","funders":"Seagen; Pfizer","keywords":"Pembrolizumab; Medicine; Oncology; Internal medicine; Antibody-drug conjugate; Chemotherapy; Metastatic Urothelial Carcinoma; Antibody; Immunotherapy; Cancer; Urothelial carcinoma; Monoclonal antibody; Immunology; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001237854,0.0002750215,0.0005884147,0.0004045576,0.0001426364,0.0004783912,0.0003426849,0.0004150601,0.002798608],"category_scores_gemma":[0.0006026846,0.0001181596,0.000476826,0.0003857198,0.0002165713,0.0003446174,0.0002279646,0.0006876627,0.0004117399],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008379862,"about_ca_system_score_gemma":0.0008458566,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007841061,"about_ca_topic_score_gemma":0.003091415,"domain_scores_codex":[0.9997413,0.0001069144,0.00003826995,0.00004082477,0.00004953917,0.00002313521],"domain_scores_gemma":[0.9997738,0.00005598154,0.00007977346,0.00001237976,0.00002631696,0.00005175368],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.05260468,0.001931004,0.003362573,0.007044938,0.0009654635,0.0003129331,0.000113235,0.001091245,0.03427118,0.001085744,0.008513587,0.8887036],"study_design_scores_gemma":[0.1678524,0.2475186,0.07338753,0.00603419,0.005715907,0.007498989,0.0002446919,0.005266054,0.08773264,0.002028514,0.3965886,0.0001317685],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6399741,0.3290243,0.001820787,0.003757141,0.0008828748,0.001800345,0.00160958,0.0002172022,0.02091378],"genre_scores_gemma":[0.9221842,0.06563849,0.003598484,0.001403423,0.0002722164,0.0005836053,0.001439499,0.000019147,0.004860925],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002798608,"threshold_uncertainty_score":0.00936228,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0126343344582403,"score_gpt":0.3140959120053023,"score_spread":0.301461577547062,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}